Conceptus to Present at the 7th Annual Needham & Company Biotechnology and Medical Technology Conference.

MOUNTAIN VIEW, Calif. -- Conceptus, Inc. (NASDAQ:CPTS) announces that Mark Sieczkarek, president and chief executive officer, will present at the Needham & Company Biotechnology and Medical Technology Conference on Wednesday, June 11, at 9:30 a.m. EDT. The conference will be held at The New York Palace Hotel from June 11 - June 12, 2008.

A live webcast of the presentation will be available by going to www.conceptus.com and clicking on the link to Live Webcasts. An archived replay will be available for a period of 30 days.

About the Essure Procedure

The Essure procedure, approved by the FDA in 2002, is a permanent birth control procedure that replaces tubal ligation for women. In the comfort of a physician's office and in about 10 minutes, the soft micro-inserts are placed into the Fallopian tubes through the cervix eliminating the need for incisions. Once in place, the device is designed to elicit tissue growth in and around the micro-insert to form an occlusion or blockage in the Fallopian tubes.

The Essure confirmation test is performed three months after the procedure to confirm that the micro-inserts are in the correct location, the tubes are blocked and that the woman can discontinue temporary birth control. The Essure procedure is 99.80% effective and is the first and only FDA approved female sterilization procedure to have zero pregnancies in clinical trials.

About Conceptus

Conceptus, Inc. manufactures and markets the Essure Permanent Birth Control system, an innovative medical device and procedure designed to provide a non-incisional alternative to tubal ligation, which is currently the leading form of birth control worldwide. The availability of the Essure procedure in the U.S. is expected to open up a market currently occupied by incisional tubal ligation and vasectomy, which combined account for over 1 million procedures annually.

Additional information about the Essure procedure is available at www.essure.com or by calling the Essure Information Center at 1-877-ESSURE1. Additional information about Conceptus is available at www.conceptus.com or by calling 1-877-ESSURE2.